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The undruggable nature of oncogenic Myc transcription factors poses a therapeutic challenge in neuroblastoma, a
pediatric cancer in which MYCN amplification is strongly associated with unfavorable outcome. Here, we show that
CYC065 (fadraciclib), a clinical inhibitor of CDK9 and CDK2, selectively targeted MYCN-amplified neuroblastoma via
multiple mechanisms. CDK9 — a component of the transcription elongation complex P-TEFb — bound to the MYCN-
amplicon superenhancer, and its inhibition resulted in selective loss of nascent MYCN transcription. MYCN loss led to
growth arrest, sensitizing cells for apoptosis following CDK2 inhibition. In MYCN-amplified neuroblastoma, MYCN invaded
active enhancers, driving a transcriptionally encoded adrenergic gene expression program that was selectively reversed
by CYC065. MYCN overexpression in mesenchymal neuroblastoma was sufficient to induce adrenergic identity and
sensitize cells to CYC065. CYC065, used together with temozolomide, a reference therapy for relapsed neuroblastoma,
caused long-term suppression of neuroblastoma growth in vivo, highlighting the clinical potential of CDK9/2 inhibition in
the treatment of MYCN-amplified neuroblastoma.
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Introduction
The prominent role of Myc family protooncogene transcription fac-
tors (TFs) (MYC, MYCN, MYCL) in the genesis of adult and child-
hood cancers makes these TFs attractive targets for drug discovery 
and development (1). However, the intrinsically disordered struc-
ture of Myc proteins and an incomplete understanding of how Myc, 
a master regulator of the transcriptomic and epigenetic landscape, 
coopts oncogenesis to drive cellular transformation are 2 major fac-
tors that impede traditional drug discovery approaches (1).
Across many cancers, a singular feature of oncogenic Myc 
activity is an increase in the abundance of its full-length protein 
(2). This suggests that Myc protein dosage itself is transforming. 
Strategies to attenuate Myc levels may be sufficient for achieving 
a therapeutic index in tumors versus normal tissues by selective-
ly targeting oncogenic programs rather than tissue maintenance 
programs where Myc regulates homeostatic ribosome biogenesis 
and cellular proliferation (3, 4). In both normal and tumor cells, 
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BET-bromodomain transcriptional coactiva-
tors and some of the transcriptional cyclin- 
dependent kinases (CDK7/9/12/13) (14–18). In 
NB and other cancers, targeting these transcrip-
tional components leads to selective downreg-
ulation of superenhancer-associated genes, 
such as MYC or MYCN, that are characterized 
by high transcription levels and rapid turnover 
of RNA. These observations have spurred fur-
ther preclinical investigation of transcriptional 
inhibition in NB. However, as almost all cells 
have superenhancers at key identity genes, it 
remains unclear how transcriptional inhibition 
can achieve selectivity, how Myc addiction is 
subverted by transcriptional inhibition to kill 
tumor cells, and how a therapeutic strategy for 
transcriptional inhibition can be implemented.
Here, in order to accelerate the clinical 
implementation of transcriptional inhibitors 
in NB, we investigate the ability of CYC065 
(fadraciclib), a selective inhibitor of CDK9 and 
CDK2 that has reached clinical early phase 
trials, to selectively target MYCN-amplified 
tumors via multiple mechanisms. CYC065 (19) and its analog 
CCT68127 (20) were discovered in a research program aimed at 
identifying derivatives of seliciclib (21) with greater potency, solu-
bility, selectivity, and metabolic stability (22).
Results
CDK9 inhibition downregulates MYCN and is selective against 
MYCN-amplified NB. We evaluated a series of clinical candidate 
drugs and tool kit compounds with potent and selective activ-
ity against CDK9 and varying activity against other CDKs. We 
observed that compounds with prominent activity against CDK9 
are efficient in downregulating MYCN to varying degrees and 
inducing apoptotic cell death, as indicated by induction of poly 
(ADP-ribose) polymerase (PARP) cleavage (Supplemental Figure 
1A and Supplemental Figure 2B; supplemental material available 
online with this article; https://doi.org/10.1172/JCI134132DS1). 
Of these compounds, we selected the chemical probe CCT68127 
(22) and its further optimized derivative CYC065 (19), which is 
in early phase clinical trials — both with significant selectivity for 
CDK9/2 (refs. 19, 20, 23 and Supplemental Figure 2, A and B). We 
evaluated CYC065 and CCT68127 across a set of NB cell lines 
(Figure 1A and Supplemental Figure 2, D and E) varying in MYCN 
amplification and protein levels and characterized for MYCN or 
MYC dependence (ref. 15 and Table 1). MYCN-driven cell lines 
exhibited time- and concentration-dependent growth inhibition, 
increased cell death (by sub-G1 population), and induction of 
apoptosis (caspase-3 and PARP cleavage), resulting in loss of cell 
viability and, with prolonged treatment, blockade of colony forma-
tion (Figure 1, B–E, and Supplemental Figure 2, C and E–H). These 
effects occurred at concentrations of CYC065 and CCT68127 
coinciding with a reduction in MYCN protein and a reduction in 
phosphorylation of RNAPII serine 2 (RNAPII Ser2P), a canonical 
substrate of CDK9 (Figure 1C and Supplemental Figure 2H). Nota-
bly, in non–MYCN-amplified NB (SH-EP, SH-SY5Y, and SK-N-AS 
Myc functions primarily as an activator of transcription. When 
bound to DNA, Myc increases proximal chromatin accessibility 
via recruitment of histone acetyltransferases (5) and drives tran-
scription elongation through recruitment of the elongation fac-
tor P-TEFb (cyclinT1:CDK9) (6) and RNA polymerase II–associ-
ated (RNAPII-associated) topoisomerases (7). A consensus has 
emerged that, when deregulated, Myc proteins act as selective 
amplifiers of gene expression (8, 9). Although Myc deregula-
tion leads to a global increase in cellular mRNA in an oncogenic 
context, transformation driven by Myc in neuroblastoma (NB), 
a developmental tumor of neural crest origin, is associated with 
selective (and enhancer dependent) upregulation of a limited set 
of lineage-related genes, expression of which normally constitutes 
a transcriptomic core regulatory circuit (CRC) that underlies neu-
ral identity and deregulation of which drives growth and prolifera-
tion of these tumors (10–12).
We and others have found that MYCN globally upregulates 
and reshapes the NB gene expression landscape through the 
invasion of tissue-specific active enhancers that establish NB 
identity (13). In particular, large superenhancers that are adjacent 
to several TFs that demarcate the recently described adrener-
gic state of NB exhibit strong MYCN binding and are selective-
ly regulated by MYCN (13). Expression of these TFs, including 
GATA3, PHOX2A, PHOX2B, HAND2/TWIST1, TBX2, and ISL1, 
is essential in MYCN-amplified NB (11, 13), suggesting that 
an oncogenic feed-forward interaction among MYCN, tissue- 
specific enhancers, and additional TFs constitutes a core regulato-
ry circuitry that underlies maintenance of lineage-related NB gene 
expression programs.
In MYCN-amplified NB, the expression of MYCN itself is 
regulated by large superenhancers that map to the MYCN ampli-
con (13). This has spurred renewed efforts to target MYCN tran-
scription through inhibition of transcriptional coregulators that 
are enriched at enhancers and superenhancers, including the 
Table 1. Genetic characteristics of cell lines
Cell lines Origin Myc status
Kelly NB MYCN amplified
BE(2)C NB MYCN amplified
IMR32 NB MYCN amplified
L-AN-5 NB MYCN amplified
SK-N-SH NB No MYCN expression
SK-N-AS NB No MYCN expression
SH-SY5Y NB No MYCN expression
SH-EP NB No MYCN expression
SH-EP (MYCN WT) NB Exogenously expressed WT MYCN protein
SH-EP (MYCN T58A) NB Exogenously expressed MYCN protein mutated at T58A
SH-EP (MYCN S62A) NB Exogenously expressed MYCN protein mutated at S62A
SH-EP (MYCN T58A and S62A) NB Exogenously expressed MYCN protein mutated at T58A and S62A
H128 Lung No MYC, MYCL or MYCN expression
H510A Lung Expressed MYCL protein
H526 Lung Expressed MYCN protein
COLO-320 Colon Expressed c-MYC protein
SKBR3 Breast Expressed c-MYC protein
HCC1954 Breast Expressed c-MYC protein
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which is only able to induce PARP cleavage at high concentrations, 
CYC065 caused extensive apoptotic cell death at cellular GI50 con-
centrations in MYCN-amplified NB cells, presumably due to con-
comitant inhibition of CDK2, itself a major regulator of apoptotic 
cell death. Apoptosis occurred concomitant with a marked reduc-
tion in MCL-1 (Supplemental Figure 1A and Supplemental Figure 
2H), a transcriptional target of CDK9 with prominent prosurvival 
activity dependent on CDK2 phosphorylation (25). Using a fluo-
rescence-based cellular sensor that measures phosphorylation of 
substrate by CDK2 (26), we confirmed that, at the GI50 concen-
tration, CYC065 reduced CDK2-driven kinase activity (Figure 
2A), blocked phosphorylation of histone H1 (a direct substrate of 
CDK2, Figure 2B), and upregulated the proapoptotic CDK2 targets 
(Supplemental Figure 4A). In contrast, NVP-2, a highly potent and 
selective CDK9-only inhibitor (27), failed to decrease CDK2 sub-
strate phosphorylation to the same degree (Figure 2A).
With extended exposure to CYC065 (8 hours), we also 
observed a reduction in phosphorylation of Rb serine 780 (Figure 
2C) and an accumulation of total and phosphorylated p53 (Supple-
cells), CYC065 still potently reduced RNAPII Ser2P at compound 
concentrations that had no or little impact on apoptosis (Supple-
mental Figure 2, I and J), suggesting that transcriptional inhibition 
is not lethal in these non–MYCN-amplified cells.
At the cellular concentration at which cell growth is inhibit-
ed by 50% (GI50), CYC065 and CCT68127 primarily caused cell 
growth arrest and apoptosis in MYCN-amplified NB cells (Figure 
1, A and B, and Supplemental Figure 2, D–F). Contrary to a report 
in lung cancer cells that CCT68127 caused anaphase catastrophe 
(18), NB cells treated with CYC065 at low concentrations exhibited 
intact mitotic spindle formation and, at higher concentrations or 
with prolonged treatment, exhibit DNA fragmentation consistent 
with apoptosis (Supplemental Figure 3A). These data suggested 
that, at concentrations close to the GI50 and therefore relevant to 
the mechanism of action for CDK9 and CDK2, CYC065 treatment 
results in growth arrest and apoptosis in MYCN-amplified cells.
Cell death upon CDK9 inhibition is enhanced by concomitant 
blockade of CDK2 activity. We observed that, in comparison with 
monoselective inhibitors of CDK9, such as compound 3 (24), 
Figure 1. CDK9 and CDK2 are selectively essential for MYCN-amplified NB. (A) GI50 of CCT68127 and CYC065 in a panel of NB cells. Cells were treated for 
8 hours, washed off, and replaced with normal growth medium. GI50 values (μM) were calculated after 72 hours (n = 3). Significance was calculated using 
2-tailed, unpaired Student’s t test. (B) Kelly cells were treated with CYC065 or CCT68127 for 0.5 to 6 hours (1 μM). Immunoblots illustrate expression of 
PARP cleavage (n = 2). (C) Immunoblots showing expression of p-RNAPII-Ser2 and p-RNAPII-Ser5, MYCN, and MCL-1 at the indicated times after treatment 
with CYC065 (1–2 μM, 1–8 hours) in Kelly cells (n = 2). (D) Flow cytometry analysis showing sub-G1 level of MYCN-amplified (Kelly, BE(2)C) and nonamplified 
(SH-EP, SK-N-AS) cells in response to CYC065 (1 μM; 8 hours). Data are represented as mean ± SD of 3 independent experiments. (E) Kelly cells were treat-
ed with CYC065 or CCT68127 at the indicated concentrations (0.5–2 μM) for 6 hours. Immunoblots depict expression of cleaved caspase-3 (n = 2).
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
4 jci.org
was modest, we performed CRISPR Cas9–mediated knockout of 
CDK2 in MYCN-amplified Kelly cells (Supplemental Figure 5G), 
which elicited minimal effects on apoptosis or cell cycle distribu-
tion (Supplemental Figure 4G), and in parental MYCN-amplified 
Kelly cells, selective chemical inhibition or genetic knockdown 
of CDK9 or CDK2 alone failed to phenocopy the growth inhibi-
tory effects of CYC065 (Figure 2E and Supplemental Figure 4G). 
Finally, we observed that only in CDK2-knockout cells did com-
pound 3 treatment or CDK9 degradation using THAL-SNS-032 
(27) (a potent and selective CDK9 degrading PROTAC) result in 
an increase in sub-G1 apoptotic cells (Supplemental Figure 4, F 
and G) and growth inhibitory effects (Figure 2E). Taken together, 
mental Figure 2H, Supplemental Figure 4, B–D, and Supplemental 
Figure 5H), both known consequences of CDK2 inhibition (15). In 
CDK9-inhibited and MYCN-dependent cells, activation of apop-
totic cell death is CDK2 dependent, as the monoselective CDK9 
chemical probe (compound 3) (24), the clinical monoselective 
CDK9 inhibitor BAY1143572 (28) (atuveciclib), and knockdown of 
CDK2 with siRNA each failed to induce robust apoptosis (Figure 2D 
and Supplemental Figure 4, E and G). In contrast to monospecific 
inhibition of CDK9 or CDK2, the combination of selective CDK9 
inhibition (Compound 3 or BAY1143572) with siRNAs directed at 
CDK2 resulted in enhanced PARP cleavage (Figure 2D and Supple-
mental Figure 4, E and G). Since the siRNA knockdown of CDK2 
Figure 2. CDK9 and CDK2 synergistically maintain MYCN-amplified NB cells. (A) CDK2 activity is 
obtained by measuring the cytoplasmic-to-nuclear ratio of DHB-mVenus. Cell nuclei were iden-
tified using DAPI staining. Bold lines represent median, boxes represent the interquartile range 
(IQR), whiskers represent 1.5 times the interquartile range, and outliers are not shown. Welch’s 
2-tailed t test with Benjamini and Hochberg correction for multiple comparison. ***P < 1 × 10–8. 
(B) Kelly cells were treated with CYC065 or DMSO and harvested after 1 hour. CDK2 complexes 
were immunoprecipitated from cell lysates followed by an in vitro kinase assay using histone 
H1 as a substrate (n = 2). (C) Kelly and BE(2)C cells were treated with CYC065 for the indicated 
concentrations (0.5–2 μM) for 8 hours. Immunoblots show expression of the Rb protein (n = 2). 
(D) Immunoblots and bar plots showing expression of MYCN and cleaved PARP when cells were 
treated with compound 3 (Cmpd 3) at 1 × GI50 and/or siRNA directed to CDK2. Data are repre-
sented as mean ± SD of 2 independent experiments. Two-tailed, unpaired Student’s t test with 
Benjamini and Hochberg correction for multiple comparisons. ***P < 0.001. (E) Proliferation of 
NB cells quantified using a CellTiter-Glo assay. Kelly cells with CRISPR Cas9–mediated knockout 
of CDK2 (KO) or endogenous (WT) CDK2 were treated with CYC065 (8 hours), Deg (THAL-SNS-032, 
8 hours), and siRNA against CDK9 or CDK2 for 48 hours. Data are represented as mean ± SD of 3 
independent experiments. Two-tailed, unpaired Student’s t test with Benjamini and Hochberg 
correction for multiple comparisons. *P < 0.05; ***P < 0.001.
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Figure 3. Inhibition of CDK9 blocks transcription of MYCN and genes 
with short half-lives. (A and B) Immunoblot and graph showing effects 
of treatment with CYC065 (6 hours) on phosphorylation of RNAPII at Ser2 
and Ser5 at the indicated concentrations in Kelly cells. Data are repre-
sented as mean ± SD of 3 independent experiments. Two-tailed, unpaired 
Student’s t test with Benjamini and Hochberg correction for multiple 
comparisons. ***P < 0.001. (C and D) Click-IT assay showing effect of 
CYC065 or CCT68127 (0.25–1 μM, 1 hours) on the abundance of newly 
synthesized nascent RNA in Kelly cells as illustrated in green fluorescence 
(C) and graph. Scale bar: 10 μm. (D). Data are represented as mean ± SD 
of 4 independent experiments. Two-tailed, unpaired Student’s t test with 
Benjamini and Hochberg correction for multiple comparisons ***P < 0.001. 
Scale bar: 10 μm. (E) Immunofluorescence showing newly synthesized 
nascent RNA (green) as described in C and FISH of MYCN gene– (red) and 
DAPI-stained nucleus (blue) following 1 hour treatment with CYC065 in 
Kelly cells (n = 3). (F) Immunoblot showing level of H3K27ac after treat-
ment with CYC065 (1 μM) for 1 hour and 6 hours (n = 1). (G) 1PCR analyses 
showing levels of MYCN and MCL-1 genes extracted from fluorescently 
labeled nascent RNA in Figure 3C. Data are represented as mean ± SD of 4 
independent experiments. Two-tailed, unpaired Student’s t test with Ben-
jamini and Hochberg correction for multiple comparisons. ***P < 0.001. (H) 
Box plot documenting gene expression changes after CYC065 treatment 
(1 μM, 1 hour) of genes with short (<5 hours, n = 386) and long (>18 hours, 
n = 380) mRNA half-lives (58). Two-tailed, unpaired Wilcoxon’s rank sum 
test. (I) GSEA in MYCN-amplified (Kelly, BE(2)C), non–MYCN-amplified 
(SK-N-AS, SH-SY5Y) NB cell lines and tumors from TH-MYCN mice after 
treatment with CYC065. Shown is the MYC target gene V2 gene set from 
the Hallmark collection of the MSigDB.
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these data confirm that in the setting of CDK9-induced MYCN 
blockade, activation of apoptotic cell death in MYCN-amplified 
NB requires concomitant diminution of CDK2 activity.
CDK9 inhibition blocks nascent transcription of MYCN and oth-
er highly transcribed genes. Together with cyclin T1, CDK9 forms 
P-TEFb, which promotes transcriptional elongation via direct 
phosphorylation of Ser2 in the carboxy-terminal repeat (CTD) 
of RNAPII (29–33). Consistent with its property of inhibiting 
CDK9, CYC065 at a GI50 concentration blocked phosphorylation 
of RNAPII Ser2, while RNAPII Ser5, a target of CDK7, was inhib-
ited only at higher concentrations (Supplemental Figure 1A and 
Figure 3, A and B). Short-term treatment (1 hour) with CYC065 
or CCT68127 globally reduced, but did not totally block, nascent 
RNA synthesis, as determined by in situ staining (Figure 3, C and 
D). In comparison, actinomycin D (ActD), which inhibits tran-
scription initiation, completely abrogated nascent transcription at 
a 0.5 μg/mL concentration. These results suggest that CDK9 inhi-
bition at least partially inhibits global transcription elongation.
Using high-resolution imaging, we noticed consistent overlap 
of nascent transcription foci at the MYCN amplicon (visualized 
by DNA FISH) that were abrogated by the exposure to the GI50 
concentration of CYC065 (Figure 3E). Loss of MYCN transcript 
temporally coincided with global loss of nascent transcription 
and chromatin acetylation, as evidenced by H3K27ac levels (Fig-
ure 3F). This is consistent with the overall role of Myc proteins 
in amplifying gene expression (8, 9) and maintaining open chro-
matin (34). Indeed, nascent transcription of highly expressed, 
high-turnover transcripts such as MYCN and MCL-1 was almost 
completely inhibited within 15 minutes of CYC065 treatment 
(Figure 3G), and overall, short half-life genes such as MYCN (Sup-
plemental Figure 5A) were selectively depleted from the cellular 
mRNA pool (Figure 3H). In contrast, CYC065 had only modest 
effects on MYCN protein turnover (Supplemental Figure 5, B 
and C). MYCN loss was phenocopied by selective degradation of 
CDK9 by THAL-SNS-032 and genetic depletion of CDK9 or to 
a lesser extent CDK7 (Supplemental Figure 5, D–F), consistent 
with a general sensitivity of MYCN to transcriptional inhibition. 
Knockdown of CDK2 did not affect MYCN levels (Figure 2D, 
Supplemental Figure 4F, and Supplemental Figure 5G). Notably, 
when MYCN was exogenously expressed, its levels were no lon-
ger sensitive to CYC065 or CCT68127 (Supplemental Figure 5H). 
These data confirm that nascent transcription of the MYCN ampl-
icon is uniquely sensitive to transcriptional perturbation and to 
inhibition of CDK9.
Further analysis of mRNA levels upon CYC065 treatment 
across a panel of MYCN-amplified NB cell lines as well as tumors 
from the MYCN-driven TH-MYCN mouse model revealed a 
selective depletion of Myc target gene expression (Figure 3I and 
Supplemental Figure 6E). This effect was confirmed at individual 
genes, on a Myc target luciferase reporter, and by showing deple-
tion of MYCN from a target gene promoter by ChIP (Supplemen-
tal Figure 5, A, I, and J). Although MYCN depletion was much 
more pronounced in MYCN-amplified NB (Supplemental Figure 
6B), depletion of Myc-driven housekeeping gene expression was 
also consistently observed in non–MYCN-amplified NB (Figure 
3I and Supplemental Figure 6, A–E), suggesting that irrespective 
of MYCN amplification status, CDK9 inhibition targets canonical 
Myc target gene signatures associated with growth and biogenesis.
MYCN enhancer invasion shapes NB-specific responses to 
CYC065. Although CYC065 downregulated canonical Myc target 
gene expression in both MYCN and non–MYCN-amplified NB, its 
highly selective effects on MYCN-amplified NB growth spurred us 
to further investigate why and how MYCN expression or amplifica-
tion induces this dependency in NB. We considered 2 hypotheses. 
First, in MYCN-amplified NB, coamplification of the MYCN gene 
locus and of distal regulatory regions is frequently observed within 
a roughly 1 Mb amplicon (13, 16). Second, when amplified, hyper-
abundant MYCN protein saturates high-affinity binding sites at 
promoters of housekeeping genes and in turn invades lower affinity 
sites at the promoters and enhancers of tissue-specific genes (13).
To test these 2 hypotheses, we performed ChIP-Seq for CDK9 
and integrated its genome-wide occupancy with our MYCN and 
chromatin landscapes (13) in MYCN-amplified NB. Addressing 
the first hypothesis, we identified strong enrichment for CDK9 at 
both the MYCN promoter and the distal superenhancer (Figure 
4A). Investigating the second hypothesis of MYCN global effects, 
we observed widespread binding of MYCN to both promoters and 
enhancers, coincident with binding of CDK9 (Figure 4B). We and 
others have shown that the effect of Myc protein transcriptional 
regulation at target genes is proportional to the amount of Myc 
present at the promoter and nearby enhancers (13, 35). At indi-
vidual loci in Kelly cells, we observed a concentration-dependent 
relationship between overall MYCN occupancy and the mag-
nitude of expression downregulation caused by CYC065 treat-
ment at 1 hour. GATA2, a developmental TF associated with the 
adrenergic state of MYCN-driven NB (10, 12), possesses abun-
dant MYCN and CDK9 binding at upstream enhancers. Its gene 
expression was potently downregulated by CYC065 without sub-
stantial perturbation of CDK9 occupancy (Figure 4C). In contrast, 
Figure 4. Pharmacologic blockade of CDK9 targets MYCN-dependent 
transcriptional landscape. (A) Gene tracks of chromatin accessibility 
(shown by ATAC-Seq, green), active chromatin marker: H3K27ac (blue) 
and CDK9 (black) occupancy at MYCN amplicon in Kelly cells. (B) Heat-
maps of H3K27ac (blue), MYCN (red), and CDK9 (black) occupancy at all 
promoters (left) or enhancers (right) ranked by H3K27ac signal. Each row 
of heatmaps suggests 1 promoter region or enhancer region. The middle of 
heatmaps indicates the TSS or enhancer centers. (C–E) Left: gene tracks 
of H3K27ac (blue), MYCN (red), and CDK9 (black) (±CYC065) occupancy 
at individual loci. ChIP-Seq occupancy is provided in units of rpm/bp. 
Canonical MYCN-binding sites (red lines) and noncanonical MYCN-bind-
ing sites (black lines) are indicated below gene tracks. Right: bar plots 
of corresponding gene expression normalized to control showing effect 
of CYC065 (1 μM; 1 hour) treatment. Data are represented as mean ± SD. 
Two-tailed Student’s t test. *P < 0.05; **P < 0.01. (F) Scatter plot of log2 
gene expression (FPKM) fold changes (CYC065; 1 μM; 1 hour) treatment vs. 
DMSO control (x axis) versus significance of the change (y axis, –log10 FDR 
value). Genes with 1.5-fold or greater change in expression at an FDR of 0.1 
or less are considered differentially expressed (blue and red). (G) The top 
5000 transcriptionally active, expressed, and MYCN-associated genes are 
ranked by MYCN load (promoter + enhancer MYCN). Box plot implicating 
the log2 mRNA fold change of the top 1000 genes and the log2 mRNA fold 
change of the other 4000 genes. Two-tailed Student’s t test. (H) Heatmap 
indicating the mRNA log2 FPKM fold change from the FPKM median of TFs 
in adrenergic (Adren) and mesenchymal (Mes) core regulatory circuitries, 
with CYC065 (1 μM; 1 hour) treatment in Kelly cells.
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the converse were true — would MYCN overexpression convert 
mesenchymal NB into a more adrenergic state? Here, we used 
the SH-EP NB cell line, which has demonstrated mesenchymal 
identity (12) and no evidence of MYCN genomic amplification or 
expression. Using retroviral transgene expression systems, we cre-
ated stable SH-EP cells overexpressing WT MYCN as well as phos-
phorylation-deficient mutants (T58A, S62A, and the combined 
T58A S62A double mutant), all under the control of an exogenous 
promoter (Figure 5A). Phosphorylation of Myc proteins at both 
the highly conserved T58 and S62 residues is required for their 
proteasome-dependent turnover, and these mutants (especially 
the T58A) are considered to be more stable and oncogenic (36). 
In contrast to endogenously MYCN-amplified NB, treatment with 
CYC065 failed to decrease exogenous MYCN levels in these cells 
(Figure 5A). Across MYCN phosphorylation-deficient mutant vari-
ants, MYCN binding at promoters and enhancers was unchanged 
upon CYC065 treatment (Supplemental Figure 7, A and B), with 
the exception of the T58A S62A double mutant, which exhibited 
a global decrease in MYCN occupancy (Supplemental Figure 7, C 
and D). These data are consistent with our prior conclusions that 
CYC065 selectively targets nascent MYCN transcription specifi-
cally in the context of endogenous MYCN amplification.
Overexpression of MYCN in SH-EP cells increases cellular 
growth rate, but also renders these cells more sensitive to growth 
inhibition induced by CYC065 treatment (Figure 5B, Supplemen-
tal Figure 2D, and Supplemental Figure 7E). This result is surpris-
ing, given that MYCN levels were not depleted in the context of 
exogenous MYCN expression. The effect was more obvious in 
the hyperstabilized MYCN phosphorylation-deficient mutants. 
For mutants containing T58A, sensitivity to CYC065 treatment 
correlated with increased PARP cleavage (Figure 5, B–D). These 
observations led us to hypothesize that MYCN overexpression 
altered the underlying cell state of SH-EP cells, potentially induc-
ing a mesenchymal to adrenergic cell state transition. Using RNA-
Seq, we profiled the transcriptomes of the various MYCN-over-
expressing SH-EP cells and compared them with parental SH-EP 
cell gene expression profiles. Across all MYCN overexpression 
variants, we observed downregulation of genes encoding for 
mesenchymal identity as defined from more general molecular 
signature databases (Figure 5E) and specifically defined in mes-
enchymal NB subtypes (Figure 5F). Loss of mesenchymal gene 
expression coincided with an increase in expression of adrener-
gic-specific NB genes (Figure 5F). Using cell count–normalized 
gene expression, we again observed that CYC065 treatment 
globally downregulated gene expression, with more than 95% 
of active genes downregulated. Only a small number of lowly 
expressed genes (<5 FPKM) are appreciably upregulated (Figure 
5G). Among downregulated genes, mesenchymal gene signatures 
were the least downregulated (Figure 5G), suggesting that mes-
enchymal-encoding genes are not strongly occupied by MYCN. 
This finding is reinforced by the data in Figure 5, H and I, show-
ing that adrenergic signatures are more strongly downregulated 
than mesenchymal signatures by CYC065. These data suggest 
that MYCN overexpression converts NB to an adrenergic state 
and that CYC065 is able to target this state independently of 
any direct action against MYCN by selectively downregulating 
MYCN-induced adrenergic gene expression.
SRSF6 and BRD3, genes with decreasing MYCN and CDK9 pro-
moter/enhancer occupancy, respectively, exhibited more mod-
est sensitivity to CYC065 (Figure 4, D and E). Overall, CYC065 
treatment leads to global downregulation of gene expression, as 
significantly downregulated genes outnumber upregulated genes 
by approximately 10:1 (Figure 4F). Ranking the top 5000 genes 
by MYCN occupancy, we found that CYC065’s effect on gene 
expression was concordant with MYCN occupancy (Figure 4G). 
Consistent with our 2 hypotheses, these data suggest that CDK9 
occupies own superenhancer and that CYC065 treatment selec-
tively downregulates genes with elevated MYCN binding at their 
promoters and enhancers.
Previously, NB tumors have been shown to adopt and inter-
convert between 2 lineage-derived and transcriptionally encoded 
states (adrenergic or mesenchymal CRCs), expression of which is 
maintained by interactions between groups of TFs and enhancers 
and superenhancers (10–12). Interestingly, TFs that make up the 
adrenergic CRC show strong interactions with MYCN. MYCN 
binds the enhancers of these TFs and cobinds with these TFs at 
other enhancers across the genome, and knockdown of these 
adrenergic CRC TFs downregulates MYCN regulation of tis-
sue-specific gene expression (10–12). With CYC065, we observed 
a selective depletion of CRC TFs driving the adrenergic state of 
NB, as compared with the perturbation of mesenchymal master 
regulator TFs (Figure 4H). Overall, these data are consistent with 
the ability of CYC065 to selectively deplete MYCN and thus pref-
erentially downregulate these highly MYCN-occupied genes that 
crosscorrelate with the MYCN-associated adrenergic gene expres-
sion program that is essential for NB growth.
CYC065 targets the adrenergic state. Observing that CYC065- 
mediated downregulation of MYCN selectively targets TFs 
defining the adrenergic NB state, we next sought to see whether 
Figure 5. CYC065 directly blocks MYCN-driven adrenergic cell identity. (A) 
Immunoblots indicate stable MYCN expression in SH-EP MYCN system with 
CYC065 treatment (1 μM; 6 hours). (B) Potency against SH-EP and SH-EP 
MYCN cells in vitro. Cells are treated with 1 μM CYC065 for 8 hours followed 
by two PBS washes. Relative cell counts were calculated using CellTiter-Glo 
assays. Data are represented as mean ± SD of 3 independent experiments. 
(C) Immunoblots depict effect of 1 μM CYC065 treatment in SH-EP and 
SH-EP MYCN cells for 6 hours and 8 hours. (D) Dot plot showing quantifi-
cation of PARP and cleaved PARP (Cl-PARP) in C. Data are represented as 
mean ± SD of 3 independent experiments. (E) GSEA in SH-EP and SH-EP 
MYCN cell lines. Anastassiou cancer mesenchymal transition signature is 
from the Hallmark collection of the Molecular Signatures Database. (F) Box 
plot showing SH-EP MYCN mRNA log2 fold change of adrenergic (ADRN) 
genes and mesenchymal (MES) genes compared with SH-EP cells. Bold 
lines represent median, boxes represent interquartile range, and whis-
kers represent 1.5 times the interquartile range. Outliers are not shown. 
Welch’s 2-tailed t test, Benjamini and Hochberg correction for multiple 
comparisons. ***P < 1 × 10–8. (G) GSEA in SH-EP and SH-EP MYCN cell lines 
after treatment with CYC065 (1 μM; 6 hours). (H) Box plot showing mRNA 
log2 fold change of TFs from median in adrenergic and mesenchymal core 
regulatory circuitries in SH-EP MYCN cells, which is caused by CYC065 (1 
μM; 6 hours) treatments. Outliers are represented as dots. Welch’s 2-tailed 
t test and Benjamini and Hochberg correction for multiple comparisons. *P 
< 0.05. (I) Box plot showing CYC065 (1 μM; 6 hours) treatment and SH-EP 
MYCN mRNA log2 fold change of adrenergic genes and mesenchymal genes. 
Outliers are not shown. Welch’s 2-tailed t test, Benjamini and Hochberg 
correction for multiple comparisons. **P < 1 × 10–4.
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with vehicle control (Figure 6D). These effects occurred at well- 
tolerated doses of CYC065 (Supplemental Figure 8D), suggesting 
a clear therapeutic index for CYC065 in the most highly aggressive 
MYCN-deregulated forms of NB.
We next determined whether CYC065 inhibition depleted 
endogenous MYCN, decreased transcriptional elongation, and 
induced apoptosis in our animal models. In MYCN-amplified Kel-
ly NB tumor xenografts, we observed rapid loss of MYCN protein, 
induction of apoptosis, and decreased RNAPII Ser2P (Figure 6F 
and Supplemental Figure 8E). In TH-ALKF1174L/TH-MYCN tumors, 
we observed selective loss of the endogenous murine Mycn allele 
and a less pronounced effect on the exogenous human MYCN 
allele (Figure 6E). These data are consistent with our prior results 
(13) establishing CDK9 as a critical regulator of endogenous 
MYCN transcription. As with the previous in vitro studies, we 
observed increases in caspase-3 and PARP cleavage concomitant 
with MYCN loss in both Kelly NB tumor xenografts and TH-MYCN 
tumors following treatment with CYC065 (Figure 6, F–H). Phar-
macodynamic effects of CYC065 treatment were also character-
ized by a change in the noninvasive functional MRI spin lattice 
relaxation time (T1) and apparent diffusion coefficient (ADC), 
which reflect a change in tissue integrity (38) and were indicative 
of further rapid reduction in tumor burden (Figure 6, I and J, and 
Supplemental Figure 8, G–I). Taken together, the data establish 
that the in vivo activity of CYC065 against MYCN-dependent NB 
tumor progression proceeds largely through transcriptional deple-
tion of MYCN, leading to increased apoptosis and rapid loss of 
tumor burden. In other cancer models with Myc deregulated and 
nonderegulated subtypes, we observed similar trends, with selec-
tive inhibition of Myc-deregulated tumors coinciding with loss of 
Myc (Supplemental Figure 8J).
Discussion
In this study, we establish that MYCN-amplified or MYCN-de-
regulated NB can be selectively targeted via combined CDK9/2 
inhibition using CYC065, an orally bioavailable and clinically 
well-tolerated compound for which testing in the pediatric patient 
population is now warranted. In the preclinical setting, several 
multi-CDK inhibitors that also inhibit both have been shown to 
have varying ability to downregulate MYCN and kill NB cells (17, 
39). Our data build upon previous preclinical (17, 39) and clinical 
studies of CDK inhibition in NB including studies of (a) dinac-
iclib, a broad spectrum, but poorly tolerated clinical inhibitor of 
CDKs (including CDK 1,2,5,9), which exhibited antiproliferative 
activity as a single agent and together with chemotherapy in NB 
cell lines and in vivo models; and (b) seliciclib (CYC202, R-ros-
covitine), an inhibitor of CDK2/5/7/9 that exhibited only partial 
activity against MYCN and was further limited by lack of poten-
cy and rapid clearance (19–23). Here, we show that the develop-
mental clinical drug CYC065 — a potent and selective CDK9/2 
inhibitor with enhanced pharmacokinetic and pharmacodynam-
ics properties — is highly effective against NB. Furthermore, we 
demonstrate mechanistically that CYC065’s effects against high-
risk MYCN-driven NB are a result of CDK9 inhibition resulting in 
selective loss of MYCN nascent transcription, which in turn leads 
to cell growth arrest and, in addition, sensitizes NB cells to apopto-
sis upon concomitant inhibition of CDK2 by the drug.
CYC065 selectively inhibits growth of MYCN-amplified NB in vivo. 
As CYC065 is currently in early phase clinical evaluation in adults, 
we investigated its efficacy in murine models of NB. CYC065 
induced significant tumor growth inhibition and increased over-
all survival in mice carrying MYCN-amplified Kelly NB tumor 
xenografts, but had weaker effects against non–MYCN-express-
ing SK-N-AS NB tumor xenografts (Figure 6, A and B), consistent 
with the modest effect on c-MYC levels (Supplemental Figure 8F). 
CYC065 had no effect on H128 tumor xenograft (Supplemental 
Figure 8A), which is a non–Myc-driven small cell lung cancer (9). In 
the extensively studied TH-MYCN murine model of NB in which 
MYCN is expressed under control of the tyrosine hydroxylase pro-
moter, we administered CYC065 either orally or by intraperitoneal 
injection (Figure 6C and Supplemental Figure 8, B and C). Here, 
single-agent CYC065 treatment resulted in robust inhibition of 
tumor growth, and together with the DNA-damaging agent temo-
zolomide, which is commonly used in the setting of treatment- 
refractory NB, we observed tumor eradication and remark-
able extension of overall survival (Figure 6C). Finally, we tested 
CYC065 in an established transgenic model of NB, in which coex-
pression of hyperactivated anaplastic lymphoma kinase (ALKF1174L, 
a clinical mutation that cosegregates with MYCN amplification in 
NB patients) drives transcriptional activation of MYCN and forma-
tion of aggressive NB (37). In the TH-ALKF1174L/TH-MYCN genet-
ically engineered mouse model (which expresses very high levels 
of murine Mycn as a consequence of direct activity of ALK on the 
endogenous Mycn promoter) (37), we observed tumor regression 
and a dramatic increase in overall survival compared with that seen 
Figure 6. CYC065 and CCT68127 inhibit MYCN-driven NB in vivo. Effects 
of CYC065 on the growth and survival of Kelly (MYCN amplified) (A) and 
SK-N-AS (nonamplified) (B) NB xenografts in mice. Data are expressed as 
mean ± SEM (log-rank Mantel-Cox test with a 5% level of significance). (C) 
Waterfall plot documenting relative changes in tumor volume at day 7 in 
the TH-MYCN GEM model. All treatment arms versus control: P < 0.001, 
2-tailed, unpaired Student’s t test incorporating Bonferroni’s correction 
(n = 5) with a 1% level of significance. Kaplan-Meier plot documenting 
survival of TH-MYCN mice. All treatment arms versus control: P < 0.01; and 
CYC065 or CCT68127 alone versus combination with temozolomide: P = 
0.02 (log-rank Mantel-Cox test with 5% level of significance. (D) Water-
fall plot documenting relative changes in tumor volume at day 7 in the 
TH-ALKF1174L/MYCN GEM model: P < 0.001, 2-tailed unpaired Student’s t 
test with 5% level of significance. Kaplan-Meier plot documenting survival 
of TH-ALKF1174L/MYCN mice: P < 0.01, log-rank Mantel-Cox test with a 5% 
level of significance) (E) Quantitative RT-PCR analyses showing levels of 
murine and human MYCN RNA in the TH-ALKF1174L/MYCN tumor follow-
ing treatment with CYC065 for 3 days (n = 3). (F) Representative images 
and quantitative analysis of H&E and immunohistochemical staining for 
cleaved capsase-3 and MYCN in the harvested tumors from A and B. Scale 
bar: 50 μm. (G and H) Immunoblot analyses of individual tumors from 
TH-MYCN model treated with CYC065 for 1 or 3 days. Data are represented 
as mean ± SD of 4 independent experiments. Two-tailed unpaired Stu-
dent’s t test with Benjamini and Hochberg correction for multiple compar-
isons. *P < 0.05; **P < 0.01. (I) Parametric functional MRI maps showing 
reduction of tumor spin lattice relaxation time T1 and an increase in ADC 
24 hours after treatment with 50 mg/kg CYC065, and their corresponding 
H&E staining. Scale bar: 100 μm. (J) Correlation between native tumor T1 
measured 24 hours after treatment with 50 mg/kg CYC065 or CCT68127 
(percentage of pretreatment value) and relative changes in tumor volume 
following treatment with 50 mg/kg CYC065 or CCT68127.
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Recent work to characterize chromatin and transcription-
al states in NB has more clearly defined how amplified MYCN 
invades enhancers and superenhancers of tissue-specific TFs 
to reshape gene expression and thereby enforce expression of a 
lineage-associated adrenergic state (10, 12). This invasion occurs 
only at oncogenic levels of MYCN and results in a highly inter-
connected and autoregulatory transcriptional circuitry in which 
MYCN regulates multiple adrenergic identity TFs (such as GATA2) 
that in turn also regulate both MYCN itself and tissue-specific 
enhancers invaded by MYCN (10, 11). Our data support a model in 
which CYC065 selectivity arises in part from the ability of CDK9 
inhibition to collapse this transcriptional regulatory circuitry 
and break the autoregulatory feedback loop maintaining MYCN 
expression and adrenergic gene expression. Our results provide 
a mechanistic basis for the observed “transcriptional addiction” 
of these NB cells and further reinforce the emerging idea that 
drugs targeting core components of the transcriptional machin-
ery can have a therapeutic index, especially in Myc-deregulated 
tumors (40). In addition to canonical enhancer or E-box–driven 
MYCN transcription, increased expression of MYCN could also 
be mediated by induction of MYCNOS (also known as NYCM), a 
regulatory antisense RNA, or other well-characterized lncRNAs 
located within the MYCN amplicon. MYCNOS transcript modu-
lates the MYCN locus by recruiting chromatin modifiers and TFs, 
resulting in enhanced MYCN expression, and therefore logically 
could be inhibited by CYC065 treatment (41). Detailed study of 
these mechanisms is a future priority. Oncogenic dysregulation of 
Myc has also been directly associated with increased translation-
al activity either through direct upregulation of rRNA and tRNA 
transcription (42–44), increased expression of core ribosomal 
proteins (45), or with perturbation of more selective mechanisms, 
such as targeting of eIF4A-mediated translational initiation (46). 
Additionally, rate-limiting control of translation taking place 
under conditions of normal tissue homeostasis is derepressed by 
oncogenic levels of Myc.
Additionally, the ability of NB tumors to interconvert between 
adrenergic and mesenchymal identity also implicates cell-state 
change as an anticipatable mechanism for achieving CYC065 
resistance that could potentially be overcome by selective target-
ing of mesenchymal identity. Mesenchymal NB tumors are char-
acterized by activated NOTCH signaling, and NOTCH-inhibiting 
γ secretase inhibitors have demonstrated some efficacy against 
NB models (47, 48). Whether combined targeting of adrenergic 
and mesenchymal identity is sufficient to establish antagonistic 
pleiotropy and further collapse NB tumors remains to be seen. 
Moreover, these data suggest that transcriptional inhibitors such 
as CYC065 will be more effective when used in combination rath-
er than as a single agent — a conclusion supported by multiple 
observations of epigenetic and cell-state–mediated resistance to 
the BET-bromodomain family of transcriptional inhibitors (49). 
In NB, the strong combined effect we observed with CYC065 in 
combination with temozolomide, which is used for therapy-resis-
tant NB, supports the addition of CYC065 as a means for selec-
tively targeting MYCN-driven adrenergic identity.
Overall, we demonstrate that dual inhibition of CDK9 and 
CDK2 attacks MYCN dependence in NB through several mech-
anisms, including (a) selective blockade of CDK9 and superen-
hancer-regulated nascent endogenous MYCN transcription; (b) 
induction of CDK9/2-mediated proapoptotic pathways; and (c) 
selective targeting of MYCN-regulated adrenergic gene expres-
sion in NB. Importantly, both CDK9 and CDK2 inhibition are 
required for maximal effect of CYC065, as CDK9 inhibition alone 
downregulates MYCN, but fails to induce robust apoptosis, and 
CDK2 knockout alone is well tolerated in NB cells. Promising 
results from Mossé and colleagues (50) and our own recent work 
(20) additionally suggest the ability of proapoptotic agents such 
as BCL2 inhibitors (e.g., venetoclax), to further enhance effects of 
transcriptional inhibition. Together, these data establish a com-
pelling therapeutic rationale for rapid clinical evaluation of dual 
CDK9/2 inhibitors and specifically the oral developmental drug 
CYC065 in MYCN-driven high-risk NB.
Methods
Cell culture. Cell lines were LGC standards and purchased from the 
European Collection of Authenticated Cell Cultures (ECACC), ATCC, 
and Leibniz Institute DSMZ-German Collection of Microorganisms 
and Cell Cultures and were cultured in RPMI-1640 (MilliporeSigma) 
or DMEM (MilliporeSigma) as recommended by the suppliers, supple-
mented with 10% FCS (Gibco; Thermo Fisher Scientific), and main-
tained at 37°C under 5% CO2 in air. All cell lines were verified by STR 
profiling and routinely tested for mycoplasma contamination.
Reagents. CYC202 (seliciclib, R-Roscovitine), CCT68127, and 
CYC065 were provided by Cyclacel Ltd. Cycloheximide (C4859) 
and ActD (A9415) were purchased from MilliporeSigma and MG132 
(1748) from Tocris Bioscience. Temozolomide, flavopiridol, palboci-
clib, dinaciclib, and SNS-032 were purchased from SelleckChem. BAY 
1145372 was purchased from Active Biochem. Compound 3 was pro-
vided by Keith Jones (ICR). THZ1 (A8882) was purchased from Strat-
ech. NVP-2 was obtained from Calla Olson, Baylor College of Medi-
cine. THAL-SNS-032 was synthesized in house (27).
Tumor cell proliferation assays. Cell proliferation assays were per-
formed as described (51) using the Sulforhodamine B (230162; SRB) 
assay or using CellTiter-Glo Luminescent Cell Viability Assay (G7571; 
Promega) and read on a Synergy HT Multi-Mode Microplate Reader 
(Biotek). GI50 values were calculated with PRISM GraphPad, and GI50 
was defined as the compound concentration at which tumor cell growth 
was inhibited by 50% compared with the vehicle control. Percentages 
of viable cells were analyzed using trypan blue exclusion method.
CDK2 activity detection. The lentivirus construct of CDK2 sensor 
was provided by Sabrina L. Spencer (University of Colorado Boulder, 
Boulder, Colorado, USA). The CDK2 sensor lentiviral particles were 
produced using second-generation packaging plasmids psPAX2 and 
pMD2.G obtained from Addgene (a gift from Thomas F. Westbrook, 
Baylor College of Medicine; Addgene plasmids 1226 and 12259). 293T 
cells were cultured in DMEM (MilliporeSigma) supplemented with 
10% FCS and transfected using TransIT-293 Transfection Reagent 
(MIR 2704; Mirus). Viral supernatant was collected 48 and 72 hours 
after infection, filtered through a 0.45 μm low-protein binding filter 
(HAWP04700; MilliporeSigma), and concentrated with a Lenti-X con-
centrator (631232; Clontech). Kelly and BE(2)C cells were transduced 
with concentrated virus in the presence of 8 μg/mL polybrene. After 
24 hours, cells were fed with DMEM with 10% FCS. mVenus-positive 
cells were collected using flow cytometry after 72 hours of infection. 
mVenus-positive cells were plated in glass-bottom 96-well microplate 
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(655892; Greiner Bio-One). After 24 hours, cells were treated with 
DMSO, 1 × GI50 NVP-2, 2 × GI50 NVP-2, or 1 × GI50 CYC065 for 2 hours, 
4 hours, 6 hours, or 8 hours. Cells were fixed by 4% paraformalde-
hyde, which was followed by DAPI staining. mVenus fluorescence was 
imaged by IC200 cytometer (ValaSciences).
Immunofluorescence. Immunofluorescence analysis was per-
formed as described (51). Briefly, cells were fixed with ice-cold 4% 
paraformaldehyde, permeabilized with 0.2% Triton X-100 in PBS, 
incubated with primary antibody Alexa Fluor 488 or Alexa Fluor 568 
secondary antibody, (Life Technologies) and visualized with a Leica 
DM2500 microscope or quantified with the InCell Analyzer 1000.
Click-iT RNA imaging kit. The Click-iT RNA Imaging Assay 
(C10330, Thermo Fisher) was used to detect newly synthesized RNA. 
Alkyne-containing nucleoside was incorporated into newly synthe-
sized RNA and detected by an azide containing an FITC fluorescent 
dye. The assay was conducted according to the manufacturer’s pro-
tocol. Briefly, cells were cotreated with 1 mM 5-ethynyl uridine and 
either DMSO, 1 μM CYC065, or 1 μM CCT68127 for 60 minutes. As 
a positive control, the general transcription inhibitor ActD (0.5 μg/
mL, 60 minutes incubation) was used. The cells were fixed and per-
meabilized as described above, incubated with Click-iT Reaction 
Cocktail, and nuclei stained with DAPI. Fluorescence was visualized 
with a Leica DM2500 microscope and quantified with the InCell Ana-
lyzer 1000. Green fluorescence indicated newly synthesized RNA. 
Nascent RNA was isolated using the Click-iT Nascent RNA Capture 
Kit (C10365, Thermo Fisher), followed by quantitative PCR (qPCR). 
Primers for PCR are listed in Table 2.
FISH. MYCN FISH (05J50-001, Abbott Molecular) was conduct-
ed according to the manufacturer’s protocol. Briefly, Kelly cells were 
treated with CYC065, fixed with Carnoy’s solution, and codenatured 
with LSI N-MYC (2q24) Spectrum Orange probe. The melting tem-
perature was set at 73°C (2 minutes) and hybridization temperature 
at 37°C (overnight). The cells were visualized using a Leica DM2500 
microscope. Non–MYCN-amplified cells, SK-N-AS and SH-EP, were 
used as controls.
Western blot. Western blot analysis was performed as described 
(51) using NuPAGE Novex 4% to 12%, and the membranes were 
exposed using a Fujifilm LAS-4000 Imager, with the Amersham ECL 
Prime Western Blotting Detection Reagent (GE Healthcare). Antibod-
ies for immunoblots are listed in Table 3.
shRNA knockdown. shRNA knockdown experiment was per-
formed using SKNBE cells, and protein was harvested 96 hours after 
virus transduction and subjected to Western blot analysis. shRNAs 
for CDK7 and CDK9 (shRNA TRC library) were purchased from 
Millipore Sigma and are listed in Table 4. SHC002 MISSION pLKO.1-
puro Non-Mammalian shRNA Control was used as negative control.
siRNA knockdown. siRNA knockdown experiments were per-
formed using Kelly cells. Protein was harvested 96 hours after trans-
fection with siRNA and Dharmafect (Dharmacon) and subjected to 
Western blot analysis. siRNAs for CDK2 (J003236-12/14) and CDK9 
(J003243-14) were purchased from Dharmacon. Nontargeting siRNA 
control was used as negative control.
Generation of CDK2 CRISPR cell lines. To generate Cas9 stable 
cell lines, Kelly cells were transduced with 1 mL virus and 8 μg/
mL Polybrene (Merck Millipore) for 48 hours, selected with 10 μg/
mL blasticidin for 10 days, sorted into single cells, and checked for 
expression of Cas9. Virus was created by transfection of 293T cells 
with Viral Power Mix (Invitrogen) and a pLenti-Cas9-2A and Blast 
plasmid (52) (a gift from Jason Moffat, University of Toronto, Toron-
to, Canada; Addgene 73310).
To generate CDK2 CRISPR stable cell lines, Cas9 stable Kelly 
cells were transduced with 1 mL virus and 8 μg/mL Polybrene (Merck 
Millipore) for 48 hours, selected with 1 μg/mL puromycin for 10 days, 
sorted into single cells, and checked for loss of expression of CDK2. 
Viruses were created by transfection of 293T cells with Viral Power 
Mix (Invitrogen) and CDK2 sgRNA (Invitrogen LentiArray Human 
CRISPR Library CRISPR id 692363). To validate CDK2 knockout, 
genomic DNA was extracted (Zymo Quick-DNA Microprep; Zymo 
Research D3020), and sequences of the locus around the putative 
Table 2. TaqMan assays
Gene Species Catalogue Number Company
MYCN Human Hs00232074 Applied BioSystems
MYCN Mouse Mm00627179_m1 Applied BioSystems
GAPDH Human Hs02758991 Applied BioSystems
GAPDH Mouse Mm03302249 Applied BioSystems
MDM2 Human Hs00242813_m1 Applied BioSystems
ODC1 Human Hs00159739 Applied BioSystems
MCL-1 Human Hs01050896 Applied BioSystems
Table 3. Antibody information
Antibody Catalog number Source Application
MYCN OP13 Merck WB, IF
MYCN Ab-16898 Abcam ChIP
MYCN sc-791 (rabbit) Insight Biotechnologies IP, ChIP
MYCN (pT58) Ab-28842 Abcam WB
MYCN (pS62) Ab-51156 Abcam WB
MCL-1 sc-819 Insight Biotechnologies WB
GAPDH 2118L New England Biolabs WB
BAX 2772 New England Biolabs WB
Bad 9292 New England Biolabs WB
PARP 9542 New England Biolabs WB
cl-parp 9541 New England Biolabs WB
caspase-3 9662 New England Biolabs WB
cl casp3 9661 New England Biolabs IHC
p53 Ab-8 Thermo Fisher Scientific WB
p-p53 Ser15 9284 New England Biolabs WB
p-RNAPII-Ser2 MMS-129R-200 Covance WB
p-RNAPII-Ser5 MMS-134R-200 Covance WB
RNApolII MMS-126R-500 Covance WB
CDK9 2316 Cell Signaling Technology WB
Cyclin T1 2098 Abcam WB
Rb 9313 Cell Signaling Technology WB
P-Rb-Ser780 9307 Cell Signaling Technology WB
CDK7 2916 Cell Signaling Technology WB
H3K27ac Ab-4729 Abcam WB
H3K27ac 8173S Cell Signaling Technology ChIP
H3 Ab-9715S Abcam WB
Actin AC-15 Abcam WB
WB, Western blot; IF, immunofluorescence.
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edit were PCR amplified using target-specific primers (CDK2 sgRNA 
[CRIPSR ID 692363] forward: 5′-CACCCTGACTACCCAAGAATT-
AG-3′; reverse: 5′-TGTCAGCCCAGAGAGGATAA-3). The resulting 
PCR products were purified (DNA clean and concentrator-25, Zymo 
Research D4033), submitted to Sanger sequencing, and analyzed 
using the ICE CRISPR Analysis Tool (https://www.synthego.com/
products/bioinformatics/crispr-analysis).
Flow cytometry. Cells were treated with CYC065 or CCT68127, 
fixed in cold 70% ethanol, and treated with 40 μg/mL propidium iodide 
(P4864; MilliporeSigma) and 100 μg/mL RNase A (19101; QIAGEN) 
before being analyzed using LSR II flow cytometer (BD Biosciences).
Promoter activity luciferase reporter assay. IMR-32 cells were trans-
fected with a MYCN promoter Renilla luciferase construct and Cypri-
dina TK control construct (SN0322s; Switchgear Genomics), replated 
to 96-well plates, and treated with compounds (1 μM) for 6 hours at 
48 hours after transfection. Luciferase reading was normalized to the 
Cypridina TK control signal.
Tandem ubiquitin binding entity pulldown. Kelly cells were treat-
ed with either DMSO or 1 μM CYC065 for the indicated times, lysed 
in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 
10% glycerol and 200 μg/mL GST-TUBE2 (UM102; Biosensors, 
2BScientific; TUBE indicates tandem ubiquitin binding entity) or in 
the absence of GST-TUBE2 for control pulldown. Pierce Glutathione 
Magnetic Beads (88821; Thermo Scientific Fisher) were used to pull 
down ubiquitinated proteins from cell lysates according to the manu-
facturer’s instructions. Ubiquitinated proteins were eluted by boiling 
beads Laemmli buffer and resolved by SDS-PAGE.
Quantitative RT-PCR and ChIP. Quantitative RT-PCR and ChIP 
analysis were performed as described (51). Fluorescence was read 
using the Step One Plus Real-Time PCR System (Applied Biosystems) 
with the TaqMan CT/CT program. Analysis was performed using Step 
One software. TaqMan assays for qPCR are listed in Table 2. Error bars 
show SD of representative replicate. Primers specific for the APEX 
gene were as follows: forward: TGAAGCGGGTGTTAGTATGATCT; 
and reverse: ACCACAAACAACAGAACGAATCT.
p53 mutational analysis. Genomic DNA was extracted from cell 
lines (QIAGEN QIAamp DNA kit). PCR amplification of exons 5 to 
9 was performed using the primers shown in Table 5. Products were 
sequenced with the original PCR primers using the BigDye Termina-
tor Cycle Sequencing Kit and an ABI 3730 Genetic Analyzer (Applied 
Biosystems). Sequences were analyzed using Mutation Surveyor soft-
ware, version 3.97 (SoftGenetics).
RNA-Seq. RNA extraction was performed by Direct-zol RNA Mini-
prep Kit (R2050; Zymo Research) with recommended DNase I diges-
tion according to the manufacturer’s instructions. All samples were 
subjected to quality control on a TapeStation instrument and only 
RNAs with RNA integrity number (RIN) greater than 8 were used for 
sequencing. External RNA spike-ins (ERCC, Ambion) were added to 
total RNA based on cell number. Total RNA and ERCC were subject-
ed to poly(A) selection (E7490; New England BioLabs Inc.). Library 
preparation of RNA-Seq was performed by using NEBNext Ultra 
Directional RNA Library Prep Kit for Illumina (E4720L; New England 
BioLabs Inc.). RNA-Seq libraries were sequenced on a NextSeq 500 
(Illumina). NCBI’s Gene Expression Omnibus (GEO) session informa-
tion for RNA-Seq experiments is in Table 6.
ChIP using tagmentation. Antibodies for ChIP using tagmentation 
(ChIPmentation) were as follows: MYCN (catalog sc-791; Santa Cruz 
Biotechnology Inc.); H3K27ac (catalog 8173S; Cell Signaling Technolo-
gy). ChIPmentation was performed as previously described (53). ChIP-
mentation libraries were sequenced on a NextSeq 500 (Illumina).
ATAC-Seq analysis. For each cell line, 50,000 cells were lysed for 
10 minutes at 4°C in lysis buffer (10 mM Tris-HCl pH 7.4, 10 mM NaCl, 
3 mM MgCl2, and 0.1% IGEPAL CA-360). After lysis, pellets were sub-
jected to a transposition reaction (37°C, 60 minutes) using 2× TD buf-
fer and transposase enzyme (Illumina Nextera DNA Preparation Kit, 
FC-121-1030). The transposition mixture was purified using a QIA-
GEN MinElute PCR Purification Kit. Library amplification was per-
formed using custom Nextera primers, and the number of total cycles 
was determined by running a SYBR dye–based qPCR reaction and cal-
culating the cycle number that corresponded to one-fourth the max-
imum. Amplified libraries were purified using a QIAGEN PCR Puri-
fication Kit and sequenced on a single lane of an Illumina NextSeq.
ChIP-Seq analysis. MYCN and H3K27ac ChIP-Seq data in the Kel-
ly cell line were obtained from Zeid et al. (13). Briefly, raw reads were 
aligned using Bowtie2 (version 2.2.1) to build version NCBI37/HG19 
(54). Alignments were performed using all default parameters except 
for –N 1. These criteria preserved only reads that mapped uniquely 
to the genome with one or fewer mismatches. All analyses were per-
formed using HG19 RefSeq gene annotations.
Normalized read density of a ChIP-Seq data set in any genomic 
region was calculated using the Bamliquidator read density calculator 
(https://github.com/BradnerLab/pipeline/wiki/bamliquidator). ChIP-
Seq reads aligning to the region were extended by 200 bp, and the den-
sity of reads per bp was calculated. The density of reads in each region 
was normalized to the total number of million mapped reads producing 
read density in units of reads per million mapped reads per bp (rpm/bp).
Regions of H3K27ac and MYCN enrichment were defined using 
the model-based analysis of ChIP-Seq (MACS), version 1.4.1, with 
peak finding algorithm at a P value threshold of 1 × 10–9 (55). Active 
promoters were defined as those with an enriched H3K27ac peak 
in the ±1 kb region flanking the transcription start site (TSS). Active 
enhancers were defined as regions of H3K27ac outside of this ±1 kb 
Table 5. Primers used for testing the TP53 mutation status
Exons PCR primer forward PCR primer reverse Size (bp)
5–6 TGTTCACTTGTGCCCTGACT TTAACCCCTCCTCCCAGAGA 467
7 CTTGCCACAGGTCTCCCCAA AGGGGTCAGAGGCAAGCAGA 237
8–9 TTGGGAGTAGATGGAGCCT AGTGTTAGACTGGAAACTTT 445
Table 4. shRNA from TRC library
shRNA Catalog number Details
Cdk9 (1) TRCN0000000495 AGGGACATGAAGGCTGCTAAT
Cdk9 (2) TRCN0000199780 GACGTCCATGTTCGAGTACTT
Cdk7 (1) TRCN0000000592 GCTGTAGAAGTGAGTTTGTAA
Cdk7 (2) TRCN0000000593 GCAGGAGACGACTTACTAGAT
SHC002 SHC002 MISSION 
pLKO.1-puro non-mammalian shRNA control
CAACAAGATGAAGAGCACCAA
Numbers in parentheses correspond to the different constructs used in 
Supplemental Figure 5, D and E.
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TSS region. For each gene, MYCN promoter and enhancer load were 
quantified as the cumulative area under the curve MYCN signal in the 
±1 kb region (promoter) or within ±50 kb of the TSS (enhancer).
To correlate expression change with MYCN load in Kelly, we 
first defined active transcribed and expressed genes as those with 
H3K27ac present in the ±1 kb TSS region and expression in the top 
50% of all genes. We ranked these genes by promoter + enhancer 
MYCN load and binned the top 5000 genes into 5 bins of 1000 genes 
each. For each bin, average MYCN load was calculated as was the 
average log2 change in mRNA levels after 1 hour CYC065 treatment 
(Figure 4G). Error bars represent the 95% CIs of the mean as empiri-
cally determined by resampling of the data with replacement (10,000 
iterations). Sequencing depth of ChIP-Seq experiments is in Table 7.
ChIPmentation analysis. MYCN and H3K27ac ChIPmentation 
data in SH-EP MYCN cells were analyzed using AQUAS TF and the 
histone ChIP-Seq pipeline (https://github.com/kundajelab/chipseq _
pipeline). All analyses were performed using HG19 RefSeq gene 
annotations. Normalized read density of a ChIPmentation data set 
in any genomic region was calculated as described in ChIP-Seq anal-
ysis. Regions of H3K27ac and MYCN enrichment were defined using 
MACS2 peak-finding algorithm built in AQUAS TF and histone ChIP-
Seq pipeline at a P value threshold of 1 × 10–5. Active promoters and 
active enhancers were defined as described in ChIP-Seq analysis.
Gene expression analysis. Total RNA was isolated from cells and 
tumor tissue using the RNAeasy Plus Minikit (QIAGEN), labeled, and 
hybridized to GeneChip human or mouse transcriptome expression 
array (Affymetrix). Results were robust multichip average (RMA) 
(56) normalized using the limma package from R, and differentially 
expressed genes were called using a linear model and empirical Bayes 
statistics from the affy package. For heatmaps showing gene expres-
sion changes, genes were filtered based on average expression (log2 
intensity value >5) and hierarchical clustering using Manhattan dis-
tance with complete linkage done in R. Gene set enrichment analyses 
(GSEA) (57) were performed with the C2 and Hallmark gene set col-
lections from MSigDB, signal2noise metric, and 1000 permutations. 
mRNA half-lives were taken from Schwanhäusser et al. (58), grouped 
in short (<5 hours) and long (>18 hours) half-life, and the log2 fold 
change in mRNA expression upon CYC065 treatment was illustrated 
as box plot. Boxes represent the first and third quartile; the middle 
line reflects the median; and whiskers extend to ×1.5 interquartile 
range. Outliers are shown as dots. P values were calculated using 
2-tailed Wilcoxon’s rank sum test. The log2 fold change of median 
of ADRN CRC or MES CRC upon the DMSO group was represented 
using a heatmap.
RNA-Seq analysis of SH-EP MYCN cell lines. Reads were aligned 
to the human reference genome hg19/GRCh37 using HISAT2 with 
parameter --no-unal. Gene expression values (fragments per kilobase 
per million reads [FPKM]) were computed using Cufflinks, version 
2.2.1, with library type fr-firststrand. Cell number–normalized FPKM 
were calculated based on ERCC RNA Spike-In Mix (Thermo Fisher 
Scientific). ADRN and MES gene sets were taken from van Gronin-
gen et al. (12), and the log2 fold change in mRNA expression upon the 
SH-EP or DMSO group was illustrated as a box plot. Boxes represent 
the first and third quartile; the middle line reflects the median; and 
whiskers extend to ×1.5 interquartile range. P values were calculated 
with 2-tailed Welch’s t test. GSEA (57) was performed with the C2 and 
Hallmark gene set collections from MSigDB, Signal2Noise metric, and 
1000 permutations. The log2 fold change of median of ADRN CRC or 
MES CRC upon the DMSO group was represented using a heatmap.
In vivo efficacy of CYC065 in human xenograft models and GEM 
mice. Female CrTac:NCr-Foxn1nu athymic nude mice (Taconic) (6 
weeks of age) were injected with either Kelly (5 × 106 cells), SK-N-AS 
(5 × 106 cells), or H128 (5 × 106 cells) subcutaneously in 1 flank and 
allowed to establish. Mice bearing NB xenografts with a mean diame-
ter of 5 mm were treated with 75 mg/kg/d CYC065 or vehicle (saline) 
dosed orally, using a 5 days on, 2 days off schedule for up to 3 weeks. 
Tumor volumes were measured by Vernier caliper across 2 perpendic-
ular diameters, and volumes were calculated according to the follow-
ing formula: V = 4/3π [(d1 + d2)/4]3 where d1 and d2 are the 2 perpen-
dicular diameters. Transgenic TH-MYCN or TH-ALKF1174L/TH-MYCN 
mice were genotyped to detect the presence of human MYCN or ALK 
transgene (59). Male or female mice with palpable tumors (30–50 
days old) were treated with 50 mg/kg of CYC065, CCT68127, vehicle 
(saline), freshly prepared 6 mg/kg temozolomide, or a combination of 
either 50 mg/kg of CYC065 or 50 mg/kg of CCT68127 with freshly 
prepared 6 mg/kg temozolomide for 2 consecutive weeks. CYC065 
or CCT68127 were dosed using a 5 days on, 2 days off schedule. Mice 
were allowed access to sterile food and water ad libitum.
MRI. Changes in tumor volume in the TH-MYCN or TH-ALKF1174L/
TH-MYCN mice were quantified using MRI on a 7T horizontal bore 
Table 6. GEO session information of RNA-Seq experiments
Sample name Series Accession
SHEP_MYCN_WT_DMSO_1 GSE145068 GSM4305685
SHEP_MYCN_WT_DMSO_2 GSE145068 GSM4305686
SHEP_MYCN_WT_DMSO_3 GSE145068 GSM4305687
SHEP_MYCN_WT_CYC065_1 GSE145068 GSM4305688
SHEP_MYCN_WT_CYC065_2 GSE145068 GSM4305689
SHEP_MYCN_WT_CYC065_3 GSE145068 GSM4305690
SHEP_MYCN_S62A_DMSO_1 GSE145068 GSM4305691
SHEP_MYCN_S62A_DMSO_2 GSE145068 GSM4305692
SHEP_MYCN_S62A_DMSO_3 GSE145068 GSM4305693
SHEP_MYCN_S62A_CYC065_1 GSE145068 GSM4305694
SHEP_MYCN_S62A_ CYC065_2 GSE145068 GSM4305695
SHEP_MYCN_S62A_ CYC065_3 GSE145068 GSM4305696
SHEP_MYCN_T58A_DMSO_1 GSE145068 GSM4305697
SHEP_MYCN_T58A_DMSO_2 GSE145068 GSM4305698
SHEP_MYCN_T58A_DMSO_3 GSE145068 GSM4305699
SHEP_MYCN_T58A_CYC065_1 GSE145068 GSM4305700
SHEP_MYCN_ T58A _ CYC065_2 GSE145068 GSM4305701
SHEP_MYCN_T58A _ CYC065_3 GSE145068 GSM4305702
SHEP_MYCN_T58A_and_S62A_DMSO_1 GSE145068 GSM4305703
SHEP_MYCN_T58A_and_S62A _DMSO_2 GSE145068 GSM4305704
SHEP_MYCN_T58A_and_S62A _DMSO_3 GSE145068 GSM4305705
SHEP_MYCN_T58A_and_S62A _CYC065_1 GSE145068 GSM4305706
SHEP_MYCN_ T58A _and_S62A _ CYC065_2 GSE145068 GSM4305707
SHEP_MYCN_T58A _and_S62A _ CYC065_3 GSE145068 GSM4305708
SHEP _DMSO_1 GSE145068 GSM4305709
SHEP_DMSO_2 GSE145068 GSM4305710
SHEP_ DMSO_3 GSE145068 GSM4305711
SHEP_ CYC065_1 GSE145068 GSM4305712
SHEP_ CYC065_2 GSE145068 GSM4305713
SHEP_ CYC065_3 GSE145068 GSM4305714
 
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
1 6 jci.org
Data availability. ChIP-Seq and RNA-Seq data have been deposited 
in the GEO database (GSE107126, GSE80151, GSE128330, GSE145068).
Statistics. Data were visualized and statistical analyses performed 
using GraphPad Prism (version 6; GraphPad Software Inc.) or the R 
statistical package. For each group of data, estimate variation was tak-
en into account and is indicated in each figure as SD or SEM. If sin-
gle data are presented, these data are representative of biological or 
technical triplicates, as indicated. Statistical analyses between groups 
with comparable variance were performed using 2-tailed unpaired 
Student’s t test unless otherwise indicated. Pearson’s tests were used 
to identify correlations among variables. Significance for all statistical 
tests is shown in figures or legends. P < 0.05 was considered signifi-
cant. No samples or animals were excluded from analysis, and group 
sizes were determined by power analyses using data previously shown 
(38, 51). Animals were randomly assigned to groups. Studies were not 
conducted blinded, with the exception of all histopathological scoring.
Study approval. All experimental protocols were monitored and 
approved by the ICR Animal Welfare and Ethical Review Body, in 
compliance with guidelines specified by the UK Home Office Animals 
MicroImaging system (Bruker Instruments) using a 3 cm birdcage coil. 
Anatomical T2-weighted coronal images were acquired through the 
mouse abdomen, from which tumor volumes were determined using 
segmentation from regions of interest (ROI) drawn on each tumor-con-
taining slice. The T1 and ADC, 2 functional MRI parameters, were also 
measured (38). At trial end, tumors were dissected and fixed with 4% 
paraformaldehyde or snap-frozen in liquid nitrogen for further analysis.
Pathology. Tissue sections were stained with H&E or specific anti-
bodies. Immunohistochemistry was performed using standard meth-
ods. Briefly, 5 μm sections were stained with antibodies, including 
heat-induced epitope retrieval of specimens using citrate buffer (pH 
6) or EDTA buffer, and scored by a consultant histopathologist.
Tumor or spleen tissue was homogenized using T-PER buffer (Ther-
mo Fisher Scientific) containing proteinase inhibitor (Roche) and a cock-
tail of phosphatase inhibitors (Santa Cruz Biotechnology Inc.). Protein 
(30 mg) was denatured in lithium dodecyl sulfate sample buffer (Invitro-
gen), separated on precast 4%–12% Bis-Tris gels (Invitrogen), and trans-
ferred to nitrocellulose membranes for Western blotting. Immunoblots 
were recorded electronically on a Fujifilm LAS-4000 scanner.
Table 7. Sequencing depth of ChIP-Seq experiments
Sample name Mapped reads Mapped % PCR cycles Peaks GEO series GEO accession
KELLY_CYC065_CDK9 41464643 96.89 12 1624 GSE107126 GSM2861546
KELLY_CYC065_H3K27AC 39901878 96.6 10 12421 GSE107126 GSM2861545
KELLY_CYC065_WCE 43932669 97.48 8 NA GSE107126 GSM2861542
KELLY_DMSO_CDK9 43875937 96.27 13 1940 GSE107126 GSM2861544
KELLY_DMSO_H3K27AC 45167019 96.5 11 13215 GSE107126 GSM2861543
KELLY_DMSO_WCE 49526849 97.54 8 NA GSE107126 GSM2861541
KELLY_MYCN 59487674 97.54 5 7074 GSE80151 GSM2113526
KELLY_WCE 44532043 92.32 5 NA GSE80151 GSM2113525
KELLY_H3K27AC 77156218 94.71 5 31429 GSE80151 GSM2113524
SHEP_MYCN_WT_DMSO_MYCN 32072864 81.1 11 17452 GSE128330 GSM3671495
SHEP_MYCN_WT_CYC065_MYCN 34010613 80.47 12 18566 GSE128330 GSM3671496
SHEP_MYCN_T58A_DMSO_MYCN 33026439 80.58 11 12174 GSE128330 GSM3671497
SHEP_MYCN_T58A_CYC065_MYCN 29785344 81.29 12 12560 GSE128330 GSM3671498
SHEP_MYCN_S62A_DMSO_MYCN 30368111 80.55 12 13636 GSE128330 GSM3671499
SHEP_MYCN_S62A_CYC065_MYCN 34846800 80.79 12 17812 GSE128330 GSM3671500
SHEP_MYCN_T58A_and_S62A_DMSO_MYCN 31945930 91.67 13 18056 GSE128330 GSM3671493
SHEP_MYCN_T58A_and_S62A_CYC065_MYCN 22719761 91.56 13 9120 GSE128330 GSM3671494
SHEP_MYCN_WT_DMSO_WCE 34846800 80.79 8 NA GSE128330 GSM3671501
SHEP_MYCN_WT_CYC065_WCE 26647343 79.58 10 NA GSE128330 GSM3671506
SHEP_MYCN_T58A_DMSO_WCE 23149810 79.95 10 NA GSE128330 GSM3671502
SHEP_MYCN_T58A_CYC065_WCE 35848374 80.34 9 NA GSE128330 GSM3671507
SHEP_MYCN_S62A_DMSO_WCE 31935621 78.09 11 NA GSE128330 GSM3671503
SHEP_MYCN_S62A_CYC065_WCE 35089754 80.63 10 NA GSE128330 GSM3671508
SHEP_MYCN_T58A_and_S62A_DMSO_WCE 22139842 91.1 15 NA GSE128330 GSM3671504
SHEP_MYCN_T58A_and_S62A_CYC065_WCE 25732969 90.63 13 NA GSE128330 GSM3671509
SHEP_MYCN_WT_DMSO_H3K27AC 23186326 92.04 8 46200 GSE128330 GSM3671483
SHEP_MYCN_WT_CYC065_H3K27AC 26878855 92.12 8 51282 GSE128330 GSM3671484
SHEP_MYCN_T58A_DMSO_H3K27AC 28514145 92 8 43864 GSE128330 GSM3671485
SHEP_MYCN_T58A_CYC065_H3K27AC 26352153 92.6 8 47768 GSE128330 GSM3671486
SHEP_MYCN_S62A_DMSO_H3K27AC 24276534 92.04 8 48365 GSE128330 GSM3671487
SHEP_MYCN_S62A_CYC065_H3K27AC 24271796 92.54 8 50834 GSE128330 GSM3671488
SHEP_MYCN_T58A_and_S62A_DMSO_H3K27AC 24707663 92.54 8 48304 GSE128330 GSM3671489
SHEP_MYCN_T58A_and_S62A_CYC065_H3K27AC 23745960 92.82 9 50624 GSE128330 GSM3671490
NA, not applicable.
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